GB201106340D0 - Composition - Google Patents

Composition

Info

Publication number
GB201106340D0
GB201106340D0 GBGB1106340.1A GB201106340A GB201106340D0 GB 201106340 D0 GB201106340 D0 GB 201106340D0 GB 201106340 A GB201106340 A GB 201106340A GB 201106340 D0 GB201106340 D0 GB 201106340D0
Authority
GB
United Kingdom
Prior art keywords
composition
antigen
immunogenic composition
human
eliciting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1106340.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1106340.1A priority Critical patent/GB201106340D0/en
Publication of GB201106340D0 publication Critical patent/GB201106340D0/en
Priority to PCT/GB2012/050802 priority patent/WO2012140424A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

An immunogenic composition comprising i) a first antigen; and ii) a second antigen linked to a toxin, wherein the composition is capable of eliciting an immune response to the first antigen when administered to a human or non-human animal. Uses of the immunogenic composition, and a pharmaceutical composition or a kit comprising the immunogenic composition.
GBGB1106340.1A 2011-04-14 2011-04-14 Composition Ceased GB201106340D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1106340.1A GB201106340D0 (en) 2011-04-14 2011-04-14 Composition
PCT/GB2012/050802 WO2012140424A2 (en) 2011-04-14 2012-04-12 Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1106340.1A GB201106340D0 (en) 2011-04-14 2011-04-14 Composition

Publications (1)

Publication Number Publication Date
GB201106340D0 true GB201106340D0 (en) 2011-06-01

Family

ID=44147021

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1106340.1A Ceased GB201106340D0 (en) 2011-04-14 2011-04-14 Composition

Country Status (2)

Country Link
GB (1) GB201106340D0 (en)
WO (1) WO2012140424A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139843A (en) * 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
EP0831901B2 (en) * 1995-06-07 2005-12-07 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines

Also Published As

Publication number Publication date
WO2012140424A3 (en) 2013-01-24
WO2012140424A2 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
EA201790109A1 (en) TOLEROGENIC SYNTHETIC NANO-MEDIA DECREASING IMMUNE RESPONSE TO THERAPEUTIC PROTEINS
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
PH12020500101A1 (en) Novel muscosal adjuvants and delivery systems
NZ628328A (en) Rna formulation for immunotherapy
CO6781540A2 (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
EP4279513A3 (en) Cytotoxicity-inducing therapeutic agent
TR201802380T4 (en) Vaccines containing benzonaphthyridine.
EA201290590A1 (en) MODIFIED TUBERCULOSIS ANTIGENS
MX2009001412A (en) Protein matrix vaccines and methods of making and administering such vaccines.
CO6751287A2 (en) Mycobacterial antigenic composition
EP4056198A3 (en) Outer membrane vesicles
MY165086A (en) Formulations of rifaximin and uses thereof
MX2014010417A (en) Adjuvanted formulations of booster vaccines.
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
EP2762154A3 (en) Vaccine composition for transdermal administration
MX2015002482A (en) Immunogenic composition.
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
AR089995A1 (en) ROTAVIRUS SUBUNITIES VACCINES, METHODS OF PREPARATION AND USE OF THE SAME
MX2015017257A (en) Compositions and methods of immunizing against c. difficile.
WO2011100508A3 (en) Methods and compositions related to glycoprotein-immunoglobulin fusions
CR20130065A (en) ANTI-VEGFR-3 ANTIBODY COMPOSITIONS
WO2011084967A3 (en) Methods and compositions for providing protective immunity in the elderly
WO2013173256A3 (en) New and improved influenza vaccines
GB201106340D0 (en) Composition
NZ606949A (en) Human papillomavirus e7 antigen compositions and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)